Krystal Biotech is trading 4.2% up at $325.83, recovering from a sharp decline following its second-quarter financial results.
- Investors are reassessing the Q2 report, which featured an EPS beat but saw VYJUVEK revenue fall short of analyst expectations.
- The stock's recovery is being supported by broader strength across the biotech sector and positive momentum in the overall market.